307 related articles for article (PubMed ID: 24086526)
21. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5.
Kong R; Jia G; Cheng ZX; Wang YW; Mu M; Wang SJ; Pan SH; Gao Y; Jiang HC; Dong DL; Sun B
PLoS One; 2012; 7(5):e37222. PubMed ID: 22666346
[TBL] [Abstract][Full Text] [Related]
22. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
23. TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines.
Yoshida S; Narita T; Koshida S; Ohta S; Takeuchi Y
Pediatr Res; 2003 Nov; 54(5):709-17. PubMed ID: 12904602
[TBL] [Abstract][Full Text] [Related]
24. Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation.
Micheau O
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29498673
[TBL] [Abstract][Full Text] [Related]
25. Control of apoptosis signaling by Apo2 ligand.
Marsters SA; Pitti RA; Sheridan JP; Ashkenazi A
Recent Prog Horm Res; 1999; 54():225-34. PubMed ID: 10548878
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
Yang F; Jove V; Buettner R; Xin H; Wu J; Wang Y; Nam S; Xu Y; Ara T; DeClerck YA; Seeger R; Yu H; Jove R
Cancer Biol Ther; 2012 May; 13(7):534-41. PubMed ID: 22406995
[TBL] [Abstract][Full Text] [Related]
27. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.
Kelley RF; Totpal K; Lindstrom SH; Mathieu M; Billeci K; Deforge L; Pai R; Hymowitz SG; Ashkenazi A
J Biol Chem; 2005 Jan; 280(3):2205-12. PubMed ID: 15520016
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
[TBL] [Abstract][Full Text] [Related]
29. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
30. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
[TBL] [Abstract][Full Text] [Related]
31. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
Ng CP; Bonavida B
Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
[TBL] [Abstract][Full Text] [Related]
32. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
33. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.
Chawla-Sarkar M; Bauer JA; Lupica JA; Morrison BH; Tang Z; Oates RK; Almasan A; DiDonato JA; Borden EC; Lindner DJ
J Biol Chem; 2003 Oct; 278(41):39461-9. PubMed ID: 12881518
[TBL] [Abstract][Full Text] [Related]
34. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.
Stadel D; Mohr A; Ref C; MacFarlane M; Zhou S; Humphreys R; Bachem M; Cohen G; Möller P; Zwacka RM; Debatin KM; Fulda S
Clin Cancer Res; 2010 Dec; 16(23):5734-49. PubMed ID: 20940278
[TBL] [Abstract][Full Text] [Related]
35. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
Lin MT; Lin CL; Lin TY; Cheng CW; Yang SF; Lin CL; Wu CC; Hsieh YH; Tsai JP
Tumour Biol; 2016 May; 37(5):6987-96. PubMed ID: 26662956
[TBL] [Abstract][Full Text] [Related]
36. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation.
Cheng H; Hong B; Zhou L; Allen JE; Tai G; Humphreys R; Dicker DT; Liu YY; El-Deiry WS
Cell Cycle; 2012 Sep; 11(17):3312-23. PubMed ID: 22895172
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
[TBL] [Abstract][Full Text] [Related]
38. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
[TBL] [Abstract][Full Text] [Related]
39. Oxidative stress-driven DR5 upregulation restores TRAIL/Apo2L sensitivity induced by iron oxide nanoparticles in colorectal cancer.
Shi Y; Wang J; Liu J; Lin G; Xie F; Pang X; Pei Y; Cheng Y; Zhang Y; Lin Z; Yin Z; Wang X; Niu G; Chen X; Liu G
Biomaterials; 2020 Mar; 233():119753. PubMed ID: 31923762
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]